TENAYA THERAPEUTICS INC(NASDAQ:TNYA) stock News

TNYA Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

13 days ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

a month ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

a month ago - By: Benzinga - Mentions: IFRX ALEC RNXT

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge

a month ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

2 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

2 months ago - By: The Motley Fool

Tenaya (TNYA) Q2 Loss Narrows 59%

10 months ago - By: Benzinga - Mentions: TNXP OPTX PRTG VCNX ...

Dow Dips Over 200 Points; US Retail Sales Top Estimates

2 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

2 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

5 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

5 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

6 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

7 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

7 months ago - By: Yahoo Finance

Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?

7 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

7 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

7 months ago - By: Stocktwits - Mentions: MLYS SWTX CSCI MGX

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

7 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

8 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Pricing of Public Offering

8 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Proposed Public Offering

8 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

9 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

10 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

10 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

a year ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

a year ago - By: Tenaya Therapeutics, Inc.

TENAYA THERAPEUTICS INC (TNYA) Stock News

TNYA Latest News, Press Relases and Analysis

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Tenaya (TNYA) Q2 Loss Narrows 59%

Dow Dips Over 200 Points; US Retail Sales Top Estimates

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Announces Pricing of Public Offering

Tenaya Therapeutics Announces Proposed Public Offering

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update